New ETF Book by Larry Connors - Click here to read more
In accordance with Section 28a of the Danish Securities Trading Act, Novo Nordisk is required on a daily basis to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.
Please find below a statement of such trading in shares issued by Novo Nordisk.
+--------------------------------------------------------------- ----+ | Name | Kurt Anker Nielsen | |---------------------------------+---------------------------------| | Reason for reporting | Member of the Board of | | | Directors | |---------------------------------+---------------------------------| | Financial instrument and ID | Novo Nordisk B DK006010261 | | code | | |---------------------------------+---------------------------------| | Type of transaction | Donation of shares (Gift) | |---------------------------------+---------------------------------| | Date of transaction | 29 October 2009 | |---------------------------------+---------------------------------| | Place of transaction | NASDAQ OMX Copenhagen | |---------------------------------+---------------------------------| | Volume of transaction | 200 shares | |---------------------------------+---------------------------------| | Total value of transaction | DKK 63,200 | +-------------------------------------------------------------------+
+-------------------------------------------------------------------+ | Name | Jesper Brandgaard | |-----------------------------+-------------------------------------| | Reason for reporting | Chief Financial Officer | |-----------------------------+-------------------------------------| | Financial instrument and ID | Novo Nordisk B DK006010261 | | code | | |-----------------------------+-------------------------------------| | Type of transaction | Exercise of options (purchase of | | | shares) | |-----------------------------+-------------------------------------| | Date of transaction | 29 October 2009 | |-----------------------------+-------------------------------------| | Place of transaction | NASDAQ OMX Copenhagen | |-----------------------------+-------------------------------------| | Volume of transaction | 500 shares | |-----------------------------+-------------------------------------| | Total value of transaction | DKK 48,750 | +-------------------------------------------------------------------+
+---------------------------------------------------------------+ | Name | Jesper Brandgaard | |----------------------------------+----------------------------| | Reason for reporting | Chief Financial Officer | |----------------------------------+----------------------------| | Financial instrument and ID code | Novo Nordisk B DK006010261 | |----------------------------------+----------------------------| | Type of transaction | Sale of shares | |----------------------------------+----------------------------| | Date of transaction | 29 October 2009 | |----------------------------------+----------------------------| | Place of transaction | NASDAQ OMX Copenhagen | |----------------------------------+----------------------------| | Volume of transaction | 500 shares | |----------------------------------+----------------------------| | Total value of transaction | DKK 157,500 | +---------------------------------------------------------------+
Definitions and background information:
Publication Publication shall take place the day after Novo Nordisk receives sufficient information on the trading. Publication is only required when the total amount of transactions of a specific board member/executive and his/her associated persons in any one calendar year has reached 5,000 euros.
Who are board members, executives and associated persons? Board members and executives are members of the Board of Directors and Executive Management, respectively, of Novo Nordisk A/S. Associated persons are defined as the following persons associated to a board member/executive: 1) spouse or cohabitant, 2) children under the age of 18 years, 3) relatives defined as brothers, sisters, parents, grandparents etc, children, grandchildren etc who have shared the same household with a board member/executive for at least one year, and 4) any legal person, including a company, a foundation or a partnership, which is controlled directly or indirectly by a board member/executive and/or a person mentioned in 1)-3), or to which a board member/executive and/or a person mentioned in 1)-3) has managerial responsibilities or economic interests substantially equivalent to the legal person.
What is trading/transaction? Trading is any kind of transaction, including shares purchased or otherwise acquired, shares sold or otherwise disposed, gifts, mortgages and grants and exercise of options, but not heritage.
What is financial instrument and ID code? Financial instrument includes shares listed on the NASDAQ OMX Copenhagen and London Stock Exchange as well as ADRs listed on New York Stock Exchange, except for ADRs held in 401(k) retirement plan by US-based employees. The ID code is the code (ISIN DK006010261) of the Novo Nordisk share on the NASDAQ OMX Copenhagen, the code (NVOB) on London Stock Exchange or the code (NVO) on New York Stock Exchange.
What is date and place of transaction? Date of transaction is the actual transaction date. The place of transaction is the actual place of transaction, ie NASDAQ OMX Copenhagen, London Stock Exchange or New York Stock Exchange.
What is volume and value of transaction? The volume of transaction is the number of shares (of DKK 1 nominal value) or other financial instruments traded. The transaction value is the number of shares traded multiplied by the transaction price. The exchange rate of the Danish Central Bank (Nationalbanken) on the date of transaction is used for calculating the transaction value in DKK in case of shares traded on London Stock Exchange and ADRs listed on New York Stock Exchange.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs over 28,500 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
For further information please contact:
Media: Investors:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
E-mail: ekh@novonordisk.com E-mail: mlau@novonordisk.com
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
E-mail: krop@novonordisk.com
In North America: In North America
Sean Clements Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
E-mail: secl@novonordisk.com E-mail: hrmm@novonordisk.com
Company Announcement no 64 / 2009
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright Copyright Hugin AS 2009. All rights reserved.
For further information please contact: Media: Elin K Hansen Tel: (+45) 4442 3450 E-mail: Email Contact In North America: Sean Clements Tel: (+1) 609 514 8316 E-mail: Email Contact Investors: Mads Veggerby Lausten Tel: (+45) 4443 7919 E-mail: Email Contact Kasper Roseeuw Poulsen Tel: (+45) 4442 4471 E-mail: Email Contact In North America Hans Rommer Tel: (+1) 609 919 7937 E-mail: Email Contact
SOURCE: Novo Nordisk A/S
http://www2.marketwire.com/mw/emailprcntct?id=80FE30EC98628E7D http://www2.marketwire.com/mw/emailprcntct?id=CAE9DFAA7B03D80D http://www2.marketwire.com/mw/emailprcntct?id=0BF71B95FB65C74B http://www2.marketwire.com/mw/emailprcntct?id=A3689103C14439E9 http://www2.marketwire.com/mw/emailprcntct?id=C74906781B85898B
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.